Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News Analysis
Nature Reviews Drug Discovery 8, 535–536 (1 July 2009) | doi:10.1038/nrd2924
Everolimus
&
Abstract
In March 2009, everolimus (Afinitor; Novartis), an inhibitor of mTOR, was approved by the US FDA for the treatment of patients with advanced kidney cancer.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
